Skip to content
Biodatica
Start free

Shanghai Henlius Biotech

Shanghai

OncologyantibodyPhase II
Compare Sign in to watch

What changed

Phase II trial registered: A Phase II Study to Evaluate the Efficacy and Safety of HLX43 + Serplulimab as Neoadjuvant Therapy in Subjects With NSCLC

6w agoTrial registeredJun 4, 2026Source filing (opens the source filing in a new tab)

Momentum

85no change

Momentum 85 out of 100, unchanged since the last recompute.

Accelerating: several high-weight events landed recently.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Phase II

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Peer position

874 pre-ticker oncology companies at Phase II

Peer ranking — where this company sits among its stage-and-area peers by momentum, and how its runway compares to the peer median — is part of the Analyst tier.

Compare seats

A ranking of the same momentum figure the feed publishes, computed live against public-filing peers. It is a relative position, not a recommendation, and it is identical for every viewer.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

  1. Trial

    PHASE2 registered

    Mar 1, 2026

    NSCLC Stage II · NOT_YET_RECRUITING · sponsor: Shanghai Pulmonary Hospital, Shanghai, China · Study on the Efficacy and Safety of JSKN016 as Neoadjuvant Therapy in Resectable Stage II-III Non-small Cell Lung Cancer Patients

    ClinicalTrials.gov · NCT07493980 (opens the source filing in a new tab)

  2. Trial

    PHASE2 registered

    Jan 20, 2026

    Non Small Cell Lung Cancer · RECRUITING · sponsor: Shanghai Henlius Biotech · A Phase II Study to Evaluate the Efficacy and Safety of HLX43 + Serplulimab as Neoadjuvant Therapy in Subjects With NSCLC

    ClinicalTrials.gov · NCT07269782 (opens the source filing in a new tab)

  3. Trial

    PHASE2 registered

    Jan 10, 2026

    NSCLC Stage II, NSCLC Stage III · RECRUITING · sponsor: Shanghai Pulmonary Hospital, Shanghai, China · Efficacy of Anti-CTLA-4 Antibody Combined With Sintilimab and Chemotherapy as Neoadjuvant Therapy for Resectable Stage II-III Non-Small Cell Lung Cancer

    ClinicalTrials.gov · NCT07410975 (opens the source filing in a new tab)

  4. Trial

    Study registered

    Apr 30, 2025

    Lung Cancer (NSCLC), Neoadjuvant Immunotherapy · WITHDRAWN · sponsor: Shanghai Pulmonary Hospital, Shanghai, China · Predictive Value of PET/CT for Efficacy of Neoadjuvant Immunotherapy in Non-small Cell Lung Cancer

    ClinicalTrials.gov · NCT06895941 (opens the source filing in a new tab)

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources